BG 1701
Alternative Names: BG-1701Latest Information Update: 03 Sep 2021
Price :
$50 *
At a glance
- Originator Guangzhou Bio-gene Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Lung cancer
Most Recent Events
- 31 Aug 2021 BG 1701 is available for licensing as of 31 Aug 2021. https://www.gzbiogene.com/english.php/Technology/index
- 31 Aug 2021 Early research in Lung cancer in China (Parenteral) (Guangzhou Bio-gene Technology website, August 2021)
- 07 Jun 2021 Guangzhou Bio-gene Technology has several patents pending for CAR-T cell technology